Open AccessA cost‐effectiveness analysis of n‐3 PUFA (Omacor ® ) treatment in post‐MI patients
Author(s) -
QUILICI S.,
MARTIN M.,
MCGUIRE A.,
ZOELLNER Y.
Publication year - 2006
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2006.01009.x
Subject(s) - medicine , cost effectiveness , quality adjusted life year , cost–benefit analysis , markov model , time horizon , markov chain , statistics , risk analysis (engineering) , physics , mathematics , ecology , quantum mechanics , biology
Summary This study evaluates the cost‐effectiveness of omacor treatment as a standard prevention measure post‐MI in the UK. A cost‐effectiveness model was developed based on the GISSI‐P trial, combining a survival and a Markov model, over a lifetime period. The base case results for Omacor , at 4 years and over a lifetime, respectively, were: Cost per QALY gained: £3,717 and £15,189; cost per life years gained (LYG): £2,812 and £12,011. The cost per death avoided at 4 years was £31,786. Deterministic and probabilistic sensitivity analyses did not change the base case results substantially. The use of Omacor as a standard post‐MI prevention treatment seems warranted in the UK, both on the basis of its efficacy, which is in addition to other prophylactic treatments as evidenced by the results of the GISSI‐P trial, and on cost‐effectiveness grounds – both at 4 years and over a lifetime's time‐horizon, using the current cost‐effectiveness thresholds.